Detalles de la búsqueda
1.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Future Oncol
; 20(6): 297-306, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916501
2.
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
JTO Clin Res Rep
; 4(4): 100483, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025119
3.
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC.
JTO Clin Res Rep
; 3(7): 100341, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35756755
4.
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Clin Cancer Res
; 28(9): 1800-1808, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35275991
5.
Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC.
Lung Cancer
; 149: 144-153, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33017726
6.
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.
Lung Cancer (Auckl)
; 10: 125-130, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32009824
7.
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.
Bosn J Basic Med Sci
; 8(4): 386-90, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19125714
8.
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.
ESMO Open
; 3(5): e000364, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30018815
9.
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
JAMA Oncol
; 4(12): e183486, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30177994
Resultados
1 -
9
de 9
1
Próxima >
>>